MLL

亜型選択性的な製品

MLL製品

  • All (12)
  • MLL阻害剤 (12)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S7265 MM-102 MM-102 (HMTase Inhibitor IX) is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM in a cell-free assay.This product may precipitate when dissolved in saline solution or PBS solution. It is recommended to prepare the stock solution in DMSO solution.
Nat Commun, 2024, 15(1):2472
Cell Rep Med, 2024, S2666-3791(24)00179-4
J Exp Clin Cancer Res, 2024, 43(1):272
S7618 MI-2 (Menin-MLL Inhibitor) MI-2 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.
ProQuest, 2023, 30484965
Cell Stem Cell, 2022, S1934-5909(22)00417-9
Life Sci Alliance, 2022, 5(4)e202101187
S7817 MI-503 MI-503 is a potent and selective Menin-MLL inhibitor with IC50 of 14.7 nM. It shows pronounced growth suppressive activity in a panel of human MLL leukemia cell lines(GI50 at 250 nM-570 nM range), but only a minimal effect in human leukemia cell lines without MLL translocations.
Sci Adv, 2024, 10(11):eadk0785
Nat Cell Biol, 2023, 25(2):258-272
J Clin Invest, 2023, 133(13)e169993
S7619 MI-3 (Menin-MLL Inhibitor) MI-3 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 648 nM.
Nat Commun, 2023, 14(1):3062
Nature, 2021, 10.1038/s41586-021-04116-8
Clin Epigenetics, 2019, 11(1):137
S7816 MI-463 MI-463 is a potent inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM.
J Clin Invest, 2023, 133(13)e169993
iScience, 2023, 26(10):107726
iScience, 2023, 26(10):107726
S7815 MI-136 MI-136 can specifically inhibit the menin-MLL interaction. It inhibits DHT-induced expression of androgen receptor (AR) target genes.
Breast Cancer Res, 2022, 24(1):52
Cancer Cell Int, 2022, 22(1):336
J Med Chem, 2020, 31
S8934 VTP50469 VTP50469 is a potent, highly selective and orally active inhibitor of Menin-MLL interaction with Ki of 104 pM. VTP50469 exhibits anti-leukemia activity.
Cell Rep Med, 2024, S2666-3791(24)00179-4
Sci Adv, 2024, 10(11):eadk0785
Cell Rep, 2023, 42(6):112547
E1290New Ziftomenib Ziftomenib (KO-539) is an oral inhibitor of menin targeting the menin–KMT2A protein-protein interaction. It exhibits antileukemic activity and induces apoptosis of acute myeloid leukemia(AML) cells.
E4679New Bleximenib oxalate Bleximenib oxalate(Menin-MLL inhibitor 24 oxalate) is an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL) . It can be used for the research of cancer.
E1782New DSP5336 DSP5336 is an oral small molecule inhibitor of menin and MLL protein interaction. DSP5336 is undergoing clinical evaluation for its use in the treatment of patients with Relapsed or Refractory Acute Leukemia.
E4994New JNJ-75276617 JNJ-75276617 (Bleximenib, Menin-MLL inhibitor 24) is an orally bioavailable, potent inhibitor of menin targeting the menin-KMT2A selective protein-protein interaction. It also acts as an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL). JNJ-75276617 displays highly potent antiproliferative activity across several acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cell lines and patient samples.
S8996 Revumenib (SNDX-5613) Revumenib(SNDX-5613) is a potent and selective inhibitor of menin-MLL binding with a Ki of 0.15 nM. SNDX-5613 shows anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8) with IC50 values ranging from 10-20 nM.
Nat Cell Biol, 2024,
Cancers (Basel), 2024, 16(7)1311
S7265 MM-102 MM-102 (HMTase Inhibitor IX) is a high-affinity peptidomimetic MLL1 inhibitor with IC50 of 0.4 μM in a cell-free assay.This product may precipitate when dissolved in saline solution or PBS solution. It is recommended to prepare the stock solution in DMSO solution.
Nat Commun, 2024, 15(1):2472
Cell Rep Med, 2024, S2666-3791(24)00179-4
J Exp Clin Cancer Res, 2024, 43(1):272
S7618 MI-2 (Menin-MLL Inhibitor) MI-2 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 446 nM.
ProQuest, 2023, 30484965
Cell Stem Cell, 2022, S1934-5909(22)00417-9
Life Sci Alliance, 2022, 5(4)e202101187
S7817 MI-503 MI-503 is a potent and selective Menin-MLL inhibitor with IC50 of 14.7 nM. It shows pronounced growth suppressive activity in a panel of human MLL leukemia cell lines(GI50 at 250 nM-570 nM range), but only a minimal effect in human leukemia cell lines without MLL translocations.
Sci Adv, 2024, 10(11):eadk0785
Nat Cell Biol, 2023, 25(2):258-272
J Clin Invest, 2023, 133(13)e169993
S7619 MI-3 (Menin-MLL Inhibitor) MI-3 (Menin-MLL Inhibitor) is a potent menin-MLL interaction inhibitor with IC50 of 648 nM.
Nat Commun, 2023, 14(1):3062
Nature, 2021, 10.1038/s41586-021-04116-8
Clin Epigenetics, 2019, 11(1):137
S7816 MI-463 MI-463 is a potent inhibitor of Menin-MLL interaction with an IC50 value of 15.3 nM.
J Clin Invest, 2023, 133(13)e169993
iScience, 2023, 26(10):107726
iScience, 2023, 26(10):107726
S7815 MI-136 MI-136 can specifically inhibit the menin-MLL interaction. It inhibits DHT-induced expression of androgen receptor (AR) target genes.
Breast Cancer Res, 2022, 24(1):52
Cancer Cell Int, 2022, 22(1):336
J Med Chem, 2020, 31
S8934 VTP50469 VTP50469 is a potent, highly selective and orally active inhibitor of Menin-MLL interaction with Ki of 104 pM. VTP50469 exhibits anti-leukemia activity.
Cell Rep Med, 2024, S2666-3791(24)00179-4
Sci Adv, 2024, 10(11):eadk0785
Cell Rep, 2023, 42(6):112547
E1290New Ziftomenib Ziftomenib (KO-539) is an oral inhibitor of menin targeting the menin–KMT2A protein-protein interaction. It exhibits antileukemic activity and induces apoptosis of acute myeloid leukemia(AML) cells.
E4679New Bleximenib oxalate Bleximenib oxalate(Menin-MLL inhibitor 24 oxalate) is an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL) . It can be used for the research of cancer.
E1782New DSP5336 DSP5336 is an oral small molecule inhibitor of menin and MLL protein interaction. DSP5336 is undergoing clinical evaluation for its use in the treatment of patients with Relapsed or Refractory Acute Leukemia.
E4994New JNJ-75276617 JNJ-75276617 (Bleximenib, Menin-MLL inhibitor 24) is an orally bioavailable, potent inhibitor of menin targeting the menin-KMT2A selective protein-protein interaction. It also acts as an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL). JNJ-75276617 displays highly potent antiproliferative activity across several acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cell lines and patient samples.
S8996 Revumenib (SNDX-5613) Revumenib(SNDX-5613) is a potent and selective inhibitor of menin-MLL binding with a Ki of 0.15 nM. SNDX-5613 shows anti-proliferative activity against multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8) with IC50 values ranging from 10-20 nM.
Nat Cell Biol, 2024,
Cancers (Basel), 2024, 16(7)1311
E1290New Ziftomenib Ziftomenib (KO-539) is an oral inhibitor of menin targeting the menin–KMT2A protein-protein interaction. It exhibits antileukemic activity and induces apoptosis of acute myeloid leukemia(AML) cells.
E4679New Bleximenib oxalate Bleximenib oxalate(Menin-MLL inhibitor 24 oxalate) is an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL) . It can be used for the research of cancer.
E1782New DSP5336 DSP5336 is an oral small molecule inhibitor of menin and MLL protein interaction. DSP5336 is undergoing clinical evaluation for its use in the treatment of patients with Relapsed or Refractory Acute Leukemia.
E4994New JNJ-75276617 JNJ-75276617 (Bleximenib, Menin-MLL inhibitor 24) is an orally bioavailable, potent inhibitor of menin targeting the menin-KMT2A selective protein-protein interaction. It also acts as an inhibitor of menin-mixed-lineage leukemia 1 (menin-MLL). JNJ-75276617 displays highly potent antiproliferative activity across several acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cell lines and patient samples.

MLL阻害剤の選択性比較

Tags: MLL inhibitor | MLL modulator | MLL regulation| MLL interaction | MLL inhibition